Brief: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z)
26/03/2025 11:38
March 26 (Reuters) - Intellia Therapeutics Inc NTLA.O: INTELLIA THERAPEUTICS ANNOUNCES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO NEXIGURAN ZICLUMERAN (NEX-Z) FOR THE TREATMENT OF TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH CARDIOMYOPATHY Source text: ID:nGNX4HqZrX Further company coverage: NTLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)